Sang-gyu Lee

Title: Innovations in Targeted Drug Delivery by Sang-gyu Lee

Introduction

Sang-gyu Lee is an accomplished inventor based in New York, NY (US). He has made significant contributions to the field of targeted drug delivery, particularly in the development of innovative liposome-based nanocarriers. His work focuses on enhancing the efficacy of therapeutic agents while minimizing side effects.

Latest Patents

Sang-gyu Lee holds a patent for "Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use." This patent describes liposome-based nanocarriers that selectively target bone marrow, thereby minimizing tumor delivery and maintaining high drug concentrations in the bone marrow compared to conventional systemic delivery. The composition of these nanocarriers can also be adjusted to target lymph nodes and other organs within the reticuloendothelial system, such as the spleen and liver. Additionally, the patent outlines methods for imaging and mapping the bone marrow and other reticuloendothelial system organs using these nanocarriers, providing high-resolution, non-invasive, and quantitative imaging via PET. This approach offers significant advantages over traditional imaging methods. Furthermore, the liposome-based carriers can stabilize and deliver radioprotectant and free radical scavenger drugs to the bone marrow, protecting it from radiation exposure and limiting adverse effects.

Career Highlights

Sang-gyu Lee is affiliated with Memorial Sloan Kettering Cancer Center, where he continues to advance research in targeted drug delivery systems. His innovative work has the potential to transform therapeutic strategies in oncology and other medical fields.

Collaborations

Sang-gyu Lee collaborates with esteemed colleagues, including Naga Vara Kishore Pillarsetty and Steven M Larson. Their combined expertise enhances the research and development of novel therapeutic approaches.

Conclusion

Sang-gyu Lee's contributions to the field of targeted drug delivery through his innovative patent demonstrate his commitment to improving patient outcomes. His work at Memorial Sloan Kettering Cancer Center continues to pave the way for advancements in medical technology.